title: Combination molecularly targeted drug therapy in metastatic melanoma: progress to date.
abstract: Previously characterized by a median overall survival of between 6 and 12 months, metastatic melanoma now has a number of novel and effective treatment options. The ability to target the mitogen-activated protein kinase (MAPK) pathway with BRAF (v-raf murine sarcoma viral oncogene homolog B1) or MEK (mitogen-activated protein kinase kinase) inhibitors can result in rapid clinical benefit, but is too often associated with limited durability of response. Resistance inevitably develops either via reactivation of the MAPK pathway or via bypass signalling pathways, such as the PI3K (phosphoinositide 3-kinase) pathway. Combination strategies are thus appealing with an aim to overcome potential resistance mechanisms. Already, the combination of the BRAF inhibitor, dabrafenib, along with the MEK inhibitor, trametinib, has shown promising results clinically and with an improved toxicity profile. Other combination strategies with agents that target the PI3K pathway, angiogenesis, and the immune system are in development or already underway, although potential overlapping toxicities require close monitoring. The currently available molecularly targeted agents that target the MAPK pathway and development of combination therapies for treatment of metastatic melanoma are discussed in further detail.
authors: Sarah Cannon Research UK, 93 Harley St, London W1G 6AD, UK.
authors: Charlotte
authors: C
authors: Lemech
authors: Jeffrey
authors: J
authors: Infante
authors: Hendrik-Tobias
authors: HT
authors: Arkenau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D058990:Molecular Targeted Therapy / Q000379:methods*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D048493:Proto-Oncogene Proteins B-raf; D020928:Mitogen-Activated Protein Kinases
references: Clin Med Insights Oncol. 2012;6:53-66
references: 22253555
references: N Engl J Med. 2010 Aug 19;363(8):711-23
references: 20525992
references: J Clin Oncol. 2013 Feb 1;31(4):482-9
references: 23248257
references: Ther Adv Med Oncol. 2012 Mar;4(2):61-73
references: 22423265
references: N Engl J Med. 2011 Jun 30;364(26):2507-16
references: 21639808
references: Lancet. 2012 May 19;379(9829):1893-901
references: 22608338
references: J Invest Dermatol. 2004 Dec;123(6):1151-61
references: 15610528
references: N Engl J Med. 2012 Jan 19;366(3):207-15
references: 22256804
references: N Engl J Med. 2012 Nov;367(18):1694-703
references: 23020132
references: Nat Rev Cancer. 2005 Oct;5(10):761-72
references: 16175177
references: Cancer Res. 2008 Jun 15;68(12):4853-61
references: 18559533
references: N Engl J Med. 2012 Feb 23;366(8):707-14
references: 22356324
references: Nat Rev Cancer. 2012 Mar 22;12(4):237-51
references: 22437869
references: N Engl J Med. 2010 Aug 26;363(9):809-19
references: 20818844
references: Mol Cancer Ther. 2008 Sep;7(9):2876-83
references: 18790768
references: N Engl J Med. 2012 Jun 28;366(26):2455-65
references: 22658128
references: N Engl J Med. 2012 Jul 12;367(2):107-14
references: 22663011
references: Lancet Oncol. 2012 Aug;13(8):773-81
references: 22805291
references: J Clin Oncol. 2008 May 1;26(13):2139-46
references: 18390968
references: Nature. 2010 Dec 16;468(7326):973-7
references: 21107323
references: N Engl J Med. 2012 Jun 28;366(26):2443-54
references: 22658127
references: J Clin Oncol. 2006 Sep 10;24(26):4340-6
references: 16908931
references: J Clin Oncol. 2011 Aug 1;29(22):3085-96
references: 21383288
references: Mol Oncol. 2008 Apr;1(4):395-405
references: 19383313
references: Nature. 2011 Nov 23;480(7377):387-90
references: 22113612
references: Nature. 2002 Jun 27;417(6892):949-54
references: 12068308
references: J Clin Oncol. 2011 Apr 1;29(10):1239-46
references: 21343559
references: Genes Chromosomes Cancer. 2010 Aug;49(8):733-45
references: 20544847
references: Cancer Res. 2010 Jul 1;70(13):5213-9
references: 20551059
references: Nature. 2010 Dec 16;468(7326):968-72
references: 21107320
references: Pigment Cell Melanoma Res. 2012 Mar;25(2):248-58
references: 22171948
references: Nature. 2010 Mar 18;464(7287):427-30
references: 20179705
references: N Engl J Med. 2012 Mar 8;366(10):925-31
references: 22397654
references: Oncotarget. 2011 Apr;2(4):336-46
references: 21505228
references: Cell. 2010 Jan 22;140(2):209-21
references: 20141835
references: Cancer Res. 2011 Apr 1;71(7):2750-60
references: 21317224
references: Cell. 2004 Mar 19;116(6):855-67
references: 15035987
references: Mol Cancer Ther. 2012 Apr;11(4):909-20
references: 22389471
references: Clin Cancer Res. 2012 May 1;18(9):2502-14
references: 22351686
references: Cancer Immunol Immunother. 2009 May;58(5):823-30
references: 19198837
references: Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20411-6
references: 19915144
references: Nature. 2010 Mar 18;464(7287):431-5
references: 20130576
references: N Engl J Med. 2011 Jun 30;364(26):2517-26
references: 21639810
references: Nat Med. 2012 Aug;18(8):1239-47
references: 22820643
references: Clin Cancer Res. 2010 Dec 15;16(24):6040-8
references: 21169256
references: N Engl J Med. 2005 Nov 17;353(20):2135-47
references: 16291983
references: J Clin Oncol. 2013 Feb 1;31(4):499-506
references: 23248252
references: Cancer Cell. 2010 Dec 14;18(6):683-95
references: 21156289
references: J Transl Med. 2010 Jul 14;8:67
references: 20630094
references: Lancet Oncol. 2013 Mar;14(3):249-56
references: 23414587
references: Nat Commun. 2012 Mar 06;3:724
references: 22395615
references: JAMA. 2011 Jun 8;305(22):2327-34
references: 21642685
references: Lancet. 2012 Jul 28;380(9839):358-65
references: 22735384
references: Cancer Res. 2008 May 1;68(9):3429-39
references: 18451171
references: Cancer J. 2011 Nov-Dec;17(6):505-11
references: 22157295
references: Mol Cancer Ther. 2006 May;5(5):1136-44
references: 16731745
references: Oncogene. 2009 Jan 8;28(1):85-94
references: 18794803
references: Cancer Cell. 2010 Nov 16;18(5):485-98
references: 21035406